Sarepta Therapeutics (SRPT) Cash from Financing Activities (2010 - 2026)

Sarepta Therapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $241000.0 for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 98.07% year-over-year to $241000.0 in Q1 2026; TTM through Mar 2026 was -$180.6 million, a 256.83% decrease from a year earlier, with the FY2025 full-year figure at -$168.3 million, down 234.88% from the prior year.
• Cash from Financing Activities improved to $241000.0 in Q1 2026 per SRPT's latest filing, from -$39.2 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $216.4 million in Q3 2022 and bottomed at -$117.8 million in Q3 2025.
• The 5-year median for Cash from Financing Activities is $10.7 million (2022), against an average of $18.5 million.
• Across the five-year window, Cash from Financing Activities soared 3567.05% in 2022 and plunged 956.22% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $10.7 million in 2022, then slumped by 81.92% to $1.9 million in 2023, then soared by 2421.41% to $49.0 million in 2024, then sank by 180.03% to -$39.2 million in 2025, then soared by 100.61% to $241000.0 in 2026.
• Per Business Quant, the three latest SRPT Cash from Financing Activities figures stand at $241000.0 (Q1 2026), -$39.2 million (Q4 2025), and -$117.8 million (Q3 2025).